Skip to main content
Tinavi Medical Technologies Co.,Ltd. logo

Tinavi Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688277 ISIN · CNE100004256 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 760 across all filing types
Latest filing 2025-08-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688277

About Tinavi Medical Technologies Co.,Ltd.

https://www.tinavi.com/

Tinavi Medical Technologies Co.,Ltd. specializes in the design, development, and commercialization of orthopedic surgical robotic systems. Its primary offering, the TiRobot system, provides a multi-functional platform for spine and trauma surgeries, supporting procedures such as pedicle screw fixation and pelvic fracture reduction. The technology incorporates high-definition 3D imaging, precise mechanical arms, and advanced navigation software to facilitate minimally invasive operations with sub-millimeter accuracy. By integrating preoperative planning with real-time intraoperative guidance, the system aims to enhance surgical precision, reduce recovery times, and minimize radiation exposure for clinical teams. The company focuses on delivering intelligent robotic solutions to hospitals and specialized surgical centers to improve the consistency and safety of complex orthopedic interventions.

Recent filings

Filing Released Lang Actions
北京德恒律师事务所关于北京天智航医疗科技股份有限公司2023年限制性股票激励计划首次及预留授予部分第二个归属期符合归属条件及作废部分限制性股票的法律意见
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by Beijing Deheng Law Firm providing an attestation on the compliance and approval of a 2023 restricted stock incentive plan (vesting and cancellation portions). It contains no financial statements, managerial analysis, or earnings data, and is not a front‐line report (annual, interim, earnings release, etc.), but rather a compliance/legal certification. Under the “Certification Rule” it should be classified as a Regulatory Filing (fallback category) rather than a financial report or formal SEC form.
2025-08-27 Chinese
第六届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing Tianzhihang Medical Technology Co., Ltd. It details the decisions made at the 22nd meeting of the 6th board, including approval of the 2025 semi-annual report and other related reports. The document references that the actual reports are published separately on the Shanghai Stock Exchange website. The document itself does not contain the full semi-annual report or detailed financial statements but rather announces the board's resolutions and approvals. The document length is short (2395 characters) and primarily serves as an announcement of board decisions and references to other reports. Therefore, it fits best under Board/Management Information (MANG) as it concerns board meeting resolutions and approvals rather than the full financial report or other categories.
2025-08-27 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The length is 3152 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. It is not an announcement of report publication but the report summary itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and contains actual financial statements and analysis. H1 2025
2025-08-27 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京天智航医疗科技股份有限公司2025 年半年度报告" which translates to "Beijing Tinavi Medical Technology Co., Ltd. 2025 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and operational details for the first half of 2025 (January 1 to June 30, 2025). The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes financial statements, management analysis, risk disclosures, and operational updates typical of an interim or quarterly report. The presence of half-year financial data and management discussion confirms it is an Interim / Quarterly Report (IR). It is not an Annual Report (10-K) because it covers only half a year, not a full fiscal year. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive financial data and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
关于增加2025年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Tianzhihang Medical Technology Co., Ltd. regarding the increase in the 2025 annual expected amount of daily related-party transactions. It details the approval process by the board and independent directors, the amounts involved, the related parties, and the rationale for the increase. The document includes financial data related to the related parties but does not contain comprehensive financial statements or a full financial report. It is a regulatory announcement about a specific corporate action (increase in related-party transaction limits) rather than a full annual or interim report, audit report, or earnings release. It is not a report publication announcement since it contains substantive information about the transaction and approvals. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-27 Chinese
关于作废2023年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Tianzhihang Medical Technology Co., Ltd. regarding the cancellation of part of the 2023 restricted stock incentive plan. It details board and supervisory meetings, approvals, and legal opinions related to the cancellation of unvested restricted shares. The content focuses on corporate governance and stock incentive plan adjustments rather than financial results or reports. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement about changes in the company's stock incentive plan, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a regulatory disclosure about corporate actions.
2025-08-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.